Skip to Content


Active Substance: interferon alfacon-1
Common Name: interferon alfacon-1
ATC Code: L03AB09
Marketing Authorisation Holder: Astellas Pharma Europe B.V.
Active Substance: interferon alfacon-1
Status: Withdrawn
Authorisation Date: 1999-02-01
Therapeutic Area: Hepatitis C, Chronic
Pharmacotherapeutic Group: Immunostimulants

Therapeutic Indication

Treatment of patients of 18 years and older with chronic hepatitis and serum markers for hepatitis C virus (HCV) infection e.g. those who have elevated serum transaminase levels without decompensated liver disease and who are positive for serum HCV-RNA (see section 4.4). Consideration should be given to current official guidance on the appropriate use of interferons for the treatment of patients with chronic hepatitis C.
Interferon alfacon-1 should be given alone mainly in case of intolerance or contraindication to ribavirin.

The marketing authorisation for Infergen has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.